210 related articles for article (PubMed ID: 26440310)
1. Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway.
Murali R; Chandramohan R; Möller I; Scholz SL; Berger M; Huberman K; Viale A; Pirun M; Socci ND; Bouvier N; Bauer S; Artl M; Schilling B; Schimming T; Sucker A; Schwindenhammer B; Grabellus F; Speicher MR; Schaller J; Hillen U; Schadendorf D; Mentzel T; Cheng DT; Wiesner T; Griewank KG
Oncotarget; 2015 Nov; 6(34):36041-52. PubMed ID: 26440310
[TBL] [Abstract][Full Text] [Related]
2. Recurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations.
Huang SC; Zhang L; Sung YS; Chen CL; Kao YC; Agaram NP; Singer S; Tap WD; D'Angelo S; Antonescu CR
Am J Surg Pathol; 2016 May; 40(5):645-55. PubMed ID: 26735859
[TBL] [Abstract][Full Text] [Related]
3. A recurrent activating PLCG1 mutation in cardiac angiosarcomas increases apoptosis resistance and invasiveness of endothelial cells.
Kunze K; Spieker T; Gamerdinger U; Nau K; Berger J; Dreyer T; Sindermann JR; Hoffmeier A; Gattenlöhner S; Bräuninger A
Cancer Res; 2014 Nov; 74(21):6173-83. PubMed ID: 25252913
[TBL] [Abstract][Full Text] [Related]
4. Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma.
Prenen H; Smeets D; Mazzone M; Lambrechts D; Sagaert X; Sciot R; Debiec-Rychter M
Oncotarget; 2015 Nov; 6(34):36418-25. PubMed ID: 26474454
[TBL] [Abstract][Full Text] [Related]
5. Active TGF-β signaling and decreased expression of PTEN separates angiosarcoma of bone from its soft tissue counterpart.
Verbeke SL; Bertoni F; Bacchini P; Oosting J; Sciot R; Krenács T; Bovée JV
Mod Pathol; 2013 Sep; 26(9):1211-21. PubMed ID: 23599148
[TBL] [Abstract][Full Text] [Related]
6. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.
Liau JY; Tsai JH; Yang CY; Lee JC; Liang CW; Hsu HH; Jeng YM
Hum Pathol; 2015 Sep; 46(9):1360-6. PubMed ID: 26190196
[TBL] [Abstract][Full Text] [Related]
7. Frequency of mitogen-activated protein kinase and phosphoinositide 3-kinase signaling pathway pathogenic alterations in EUS-FNA sampled malignant lymph nodes in rectal cancer with theranostic potential.
Gleeson FC; Kipp BR; Voss JS; Campion MB; Minot DM; Tu ZJ; Klee EW; Graham RP; Lazaridis KN; Henry MR; Levy MJ
Gastrointest Endosc; 2015 Sep; 82(3):550-6.e1. PubMed ID: 25887718
[TBL] [Abstract][Full Text] [Related]
8. Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis.
Beca F; Krings G; Chen YY; Hosfield EM; Vohra P; Sibley RK; Troxell ML; West RB; Allison KH; Bean GR
Mod Pathol; 2020 Aug; 33(8):1518-1526. PubMed ID: 32123305
[TBL] [Abstract][Full Text] [Related]
9. Comparative genomic hybridization in four angiosarcomas of the female breast.
Baumhoer D; Gunawan B; Becker H; Füzesi L
Gynecol Oncol; 2005 May; 97(2):348-52. PubMed ID: 15863129
[TBL] [Abstract][Full Text] [Related]
10. Array CGH analysis identifies two distinct subgroups of primary angiosarcoma of bone.
Verbeke SL; de Jong D; Bertoni F; Sciot R; Antonescu CR; Szuhai K; Bovée JV
Genes Chromosomes Cancer; 2015 Feb; 54(2):72-81. PubMed ID: 25231439
[TBL] [Abstract][Full Text] [Related]
11. Genomically Complex Human Angiosarcoma and Canine Hemangiosarcoma Establish Convergent Angiogenic Transcriptional Programs Driven by Novel Gene Fusions.
Kim JH; Megquier K; Thomas R; Sarver AL; Song JM; Kim YT; Cheng N; Schulte AJ; Linden MA; Murugan P; Oseth L; Forster CL; Elvers I; Swofford R; Turner-Maier J; Karlsson EK; Breen M; Lindblad-Toh K; Modiano JF
Mol Cancer Res; 2021 May; 19(5):847-861. PubMed ID: 33649193
[TBL] [Abstract][Full Text] [Related]
12. Angiosarcoma and anaplastic carcinoma of the thyroid are two distinct entities: a morphologic, immunohistochemical, and genetic study.
Kuhn E; Ragazzi M; Ciarrocchi A; Torricelli F; de Biase D; Zanetti E; Bisagni A; Corrado S; Uccella S; La Rosa S; Bongiovanni M; Losito S; Piana S
Mod Pathol; 2019 Jun; 32(6):787-798. PubMed ID: 30723294
[TBL] [Abstract][Full Text] [Related]
13. RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas.
Serrano C; Romagosa C; Hernández-Losa J; Simonetti S; Valverde C; Moliné T; Somoza R; Pérez M; Vélez R; Vergés R; Domínguez R; Carles J; Ramón Y Cajal S
Cancer; 2016 Jan; 122(1):99-107. PubMed ID: 26479291
[TBL] [Abstract][Full Text] [Related]
14. Distinct genomic landscapes in radiation-associated angiosarcoma compared with other radiation-associated sarcoma histologies.
Dermawan JK; Chi P; Tap WD; Rosenbaum E; D'Angelo S; Alektiar KM; Antonescu CR
J Pathol; 2023 Aug; 260(4):465-477. PubMed ID: 37350195
[TBL] [Abstract][Full Text] [Related]
15. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
Zuo H; Nakamura Y; Yasuoka H; Zhang P; Nakamura M; Mori I; Miyauchi A; Kakudo K
Pathol Int; 2007 Jan; 57(1):12-20. PubMed ID: 17199737
[TBL] [Abstract][Full Text] [Related]
16. Oral and salivary gland angiosarcoma: a clinicopathologic study of 29 cases.
Fanburg-Smith JC; Furlong MA; Childers EL
Mod Pathol; 2003 Mar; 16(3):263-71. PubMed ID: 12640107
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations.
Pohl G; Ho CL; Kurman RJ; Bristow R; Wang TL; Shih IeM
Cancer Res; 2005 Mar; 65(5):1994-2000. PubMed ID: 15753399
[TBL] [Abstract][Full Text] [Related]
18. Activating mutations in the RAS/mitogen-activated protein kinase signaling pathway in sporadic trichoblastoma and syringocystadenoma papilliferum.
Shen AS; Peterhof E; Kind P; Rütten A; Zelger B; Landthaler M; Berneburg M; Hafner C; Groesser L
Hum Pathol; 2015 Feb; 46(2):272-6. PubMed ID: 25532942
[TBL] [Abstract][Full Text] [Related]
19. Activating FGFR2-RAS-BRAF mutations in ameloblastoma.
Brown NA; Rolland D; McHugh JB; Weigelin HC; Zhao L; Lim MS; Elenitoba-Johnson KS; Betz BL
Clin Cancer Res; 2014 Nov; 20(21):5517-26. PubMed ID: 24993163
[TBL] [Abstract][Full Text] [Related]
20. Treatment of consistent BRAF/HRAS gene mutation and MYC amplification radiation-induced abdominal wall angiosarcoma with low-dose apatinib: a case report.
Guan J; Luo Z; Xiao Z; Xie Y; Lin L
BMC Cancer; 2019 Dec; 19(1):1188. PubMed ID: 31805975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
